Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials

Jinkyeong Park, Jung Su Lee, Chinkook Rhee, and Yeon-Mok Oh

1Department of Critical Care, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; 2Department of Pulmonary and Critical Care Medicine, and 3Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul; 4Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Received: 18 March 2015 Accepted: 1 July 2015

Address for Correspondence: Yeon-Mok Oh, MD Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea Tel: +82.2-3010-3136, Fax: +82.2-3010-6968 E-mail: ymoh55@amc.seoul.kr

We investigated the effects of indacaterol on cough and phlegm in patients with stable chronic obstructive pulmonary disease (COPD). We performed a meta-analysis with five randomized controlled trials (RCTs) of indacaterol in stable COPD patients. The symptom severity was defined using the St. George’s Respiratory Questionnaire (SGRQ). We analyzed patients treated with 150 μg (n = 945) and 300 μg (n = 832) out of 3,325 patients who completed the SGRQ from five RCTs. After a 12-week treatment of 150 μg indacaterol, cough improvement was reported in 36.5% (316/866) of patients treated with indacaterol vs. 32.2% (259/804) of patients treated with placebo (Relative Ratio [RR], 1.13; 95% confidence interval [CI], 0.99-1.29). Phlegm improvement was reported in 31.0% (247/798) of patients treated with indacaterol vs. 30.6% (225/736) of patients treated with placebo (RR, 1.01; 95% CI, 0.87-1.18). Dyspnea improvement was reported in 39.5% (324/820) of patients treated with indacaterol vs. 31.5% (237/753) patients treated with placebo (RR, 1.33; 95% CI, 1.03-1.71; P = 0.001, I² = 55.1%). Only dyspnea improvement was significant compared to placebo even at the 300 μg indacaterol dose. Compared to placebo, a 12-week treatment of the long-acting beta-agonist, indacaterol might not have a significant effect on cough or phlegm in stable COPD.

Keywords: Pulmonary Disease, Chronic Obstructive; Indacaterol; Procaterol; Cough; Phlegm; Dyspnea

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is characterized by airway inflammation and progressive airflow obstruction, most commonly caused by cigarette smoking. Airflow limitation is measured via the FEV₁ (forced expiratory volume in the first second) and recognized symptomatically as dyspnea. Fletcher and Peto (1) reported that the degree of airflow obstruction was a predictor of mortality. FEV₁ is used as the main parameter in the evaluation of many aspects of COPD (2). Dyspnea is also a useful measure of COPD, because this symptom is closely related to the patient’s quality of life. Some studies have reported that mortality increases according to the severity of dyspnea in the patients with stable COPD (3-5).

In addition to dyspnea, cough and phlegm are the major symptoms reported by COPD patients (6). Cough and phlegm are in fact reported as frequently as dyspnea in COPD patients (the frequency of cough, phlegm, and dyspnea have been reported as 70%, 60%, and 67%, respectively). Cough and phlegm are also important, because the presence of cough and sputum identifies patients at greater risk of subsequent exacerbation as defined by the need for antibiotics or corticosteroids (7, 8). Although many clinical trials have revealed that dyspnea in COPD patients is improved by inhaled bronchodilators, the effect of these inhalers on cough or phlegm has rarely been evaluated. In recent years, new 24-hr, ultra-long-acting β-agonists such as indacaterol appear to have had a greater effect on inspiratory capacity, a marker of hyperinflation (9, 10). The improvement of dyspnea symptoms was reported to be concomitant with decreased hyperinflation in one previous systematic review and meta-analysis (11). However, the effect of indacaterol on cough and phlegm was not evaluated in that report, despite almost all studies on indacaterol reporting a beneficial effect on dyspnea in COPD patients. Therefore, we aimed in our current study to investigate the effects of indacaterol on the symptoms of cough and phlegm in stable COPD patients.

MATERIALS AND METHODS

We included five randomized controlled trials (RCTs) conducted by Novartis i.e. B1302 (12), B2334 (13), B2335S (14), B2336 (15), and B2346 (16) in which 150 μg or 300 μg per day of indacaterol was compared with placebo in stable COPD patients. In our current analysis, we compared the effect of 150 μg or 300 μg per day of indacaterol with placebo according to the ratio of patients with respiratory symptom improvement after 12 weeks of treat-
ment. We obtained the unpublished symptom scores of the St. George’s Respiratory Questionnaire (SGRQ) data from the five RCTs at baseline and after 12 weeks of indacaterol treatment.

The SGRQ symptom score was zero if symptom of cough, phlegm, or dyspnea existed not at all; 1, only with lung or respiratory infections; 2, a few days a month; 3, several days a week; 4, almost every day. In our current analysis, we only included the patients who reported symptoms of cough, phlegm, or dyspnea (i.e., ≥ 1 of the above scores) at baseline. The improvement of symptoms denoted a lower score at 12 weeks than at baseline. We performed separate analyses for the comparison of 150 μg of indacaterol versus placebo and for 300 μg indacaterol versus placebo.

Additionally, we performed a subgroup analysis in which we excluded the patients who reported cough, sputum, or dyspnea only with lung or respiratory infections in addition to the patients who did not report symptom at all.

### Statistical analysis
A relative ratio (RR) was used to evaluate treatment effects on the major symptoms - cough, phlegm, and dyspnea - comparing the indacaterol groups with the placebo group. The data were inspected to determine whether an analysis with a random effects model using the method of Der Simonian and Kacker (17), with the estimate of heterogeneity being taken from the inverse-variance fixed-effect model (18), was required. We calculated the 95% confidence intervals around the RRs. The weights as a percentage of the overall total were applied to find the interaction within each subgroup separately. Statistical heterogeneity between trials was analyzed using a chi-square test and by the I² statistic. A test of whether the summary effect measure is equal to the null was performed, as well as a test for heterogeneity (i.e., whether the true effect in all studies is the same). Heterogeneity was also quantified using the I-squared measure (18). I² values greater than 25%, 50%, and 75% were considered evidence of low, moderate, and high statistical heterogeneity, respectively. Meta-analyses were conducted using meta-command in Stata SE 13.1 for Mac (StataCorp., College Station, TX, USA).

### Ethics statement
The study protocol was approved by the institutional review board of Asan Medical Center (#2012-1044). Informed consent was not required due to its study nature of meta-analysis.

### RESULTS
The five studies included in our analysis performed trials on

---

**Table 1. Baseline characteristics of the previous reports included in this study**

| Author | Number of participant | Study period | Study duration | Study site | Study design |
|--------|-----------------------|--------------|----------------|------------|--------------|
| To et al. | 150 μg: 114 (Asian: 100%), 300 μg: 116 (Caucasian: 97%), Placebo: 117 (Caucasian: 94%) | 11/2008-10/2009 | 12 weeks | Japan, Taiwan, Korea, India, Hong Kong, Singapore | Double-blind, placebo-controlled, parallel-group study |
| Dahl et al. | 150 μg: 437, 300 μg: 432 (Asian: 100%), Placebo: 432 (Asian: 94%) | 11/2007-1/2009 | 52 weeks | 25 countries in Europe and Russia, Argentina, Chile, Colombia, Ecuador, Egypt, Israel, Peru, South Korea | Multi-center, double-blind, placebo controlled |
| Donohue et al. | 150 μg: 416 (Caucasian: 92%-94%), 300 μg: 416 (Caucasian: 92%-94%), Placebo: 418 (Caucasian: 92%-94%) | 4/23/2007-8/23/2008 | 26 weeks | Argentina, Canada, Germany, India, Italy, Korea, Spain, Sweden, Turkey, Taiwan, US | Randomized to double-blind, two stages in an adaptive seamless design |
| Kormann et al. | 150 μg: 330, 300 μg: 330 (Caucasian: 97%), Placebo: 335 (Caucasian: 95%) | 11/2007-1/2009 | 26 weeks | 142 centers in Canada, Colombia, Europe and Russia, Slovakia, India, Peru, Taiwan | Multi-center, double-blind, placebo controlled |
| Feldman et al. | 150 μg: 211, 300 μg: 211 (Caucasian: 97%), Placebo: 205 (Caucasian: 95%) | Not reported | 12 weeks | US, Australia/New Zealand, Belgium | Multi-center, double-blind, placebo controlled, parallel-group |

Data represent the mean ± standard deviation (SD) or median (upper and lower quartiles).
3,547 patients with COPD (Table 1). A total of 3,325 of these patients completed the SGRQ (945 patients treated with 150 μg of indacaterol and 832 patients treated with 300 μg of indacaterol). Four of 5 studies compared 150 μg of indacaterol and 3 of them compared 300 μg of indacaterol with placebo. There was no significant difference in age, sex, smoking, or baseline FEV1 between the indacaterol and placebo groups.

**Indacaterol 150 μg versus placebo**

At baseline, a cough (i.e., symptom score ≥ 1) was reported in 866 patients allocated to the 150 μg indacaterol group and 804 patients in the placebo group (Table 2). After 12 weeks of treatment, an improvement of the cough was reported in 316 (36.6%) patients in the indacaterol group and 247 (31.0%) patients in the indacaterol group and 247 (31.0%) patients in the placebo group (Relative Ratio [RR], 1.03; 95% confidence interval [CI], 0.98-1.09; P = 0.66, I² = 0.0%; Fig. 1A).

At baseline, phlegm was reported in 798 patients allocated to the indacaterol group and 736 patients in the placebo group (Table 2). At 12 weeks after treatment, an improvement in phlegm production was reported in 247 (31.0%) patients in the indacaterol group and 212 (33.6%) patients in the placebo group (RR, 1.29; 95% CI, 0.98-1.70; P < 0.001, I² = 68.3%; Fig. 1C).

In the subgroup of patients with symptom score ≥ 2 at baseline, an improvement of dyspnea was reported in 370 (45.7%) patients in the indacaterol group and 246 (33.7%) patients in the placebo group (RR, 1.36; 95% CI, 1.20-1.54; P < 0.001, I² = 0%).

**Indacaterol 300 μg versus placebo**

At baseline, a cough (i.e., symptom score ≥ 1) was reported in 714 patients allocated to the 300 μg indacaterol group and 678 patients in the placebo group (Table 2). After 12 weeks of treatment, an improvement in cough was reported in 272 (38.1%) patients in the indacaterol group and 226 (33.3%) patients in the placebo group (RR, 1.07; 95% CI, 0.93-1.25; P = 0.043, I² = 25.7%; Fig. 2A).

At baseline, phlegm was reported in 694 patients allocated to the indacaterol group and 623 patients in the placebo group. After 12 weeks of treatment, an improvement in phlegm was reported in 209 (30.1%) patients in the indacaterol group and 188 (30.2%) patients in the placebo group (RR, 0.99; 95% CI, 0.84-1.18; P = 0.98, I² = 0%; Fig. 2B).

At baseline, dyspnea was reported in 699 patients allocated to the indacaterol group and 631 patients in the placebo group. After 12 weeks of treatment, an improvement in dyspnea was reported in 306 (43.8%) patients in the indacaterol group and 212 (33.6%) patients in the placebo group (RR, 1.29; 95% CI, 0.98-1.70; P < 0.001, I² = 68.3%; Fig. 2C).

In the subgroup of patients with symptom score ≥ 2 at baseline, an improvement of cough was reported in 258 (36.6%) patients in the indacaterol group and 212 (40.6%) patients in the placebo group (RR, 0.89; 95% CI, 0.58-1.37; P = 0.083, I² = 87.6%). An improvement of phlegm was reported in 196 (30.4%) patients in the indacaterol group and 172 (30.0%) patients in the placebo after 12 weeks of treatment (RR, 1.01; 95% CI, 0.85-1.20; P = 0.88, I² = 0.0%). An improvement of dyspnea was reported in 340 (48.8%) patients in the indacaterol group and 223 (35.1%) patients in the placebo group after 12 weeks of treatment (RR, 1.39; 95% CI, 1.13-1.70; P < 0.001, I² = 55.0%).

**Table 2. Proportion of patients with respiratory symptoms at baseline**

| Study ID | Author | Number of participants who completed the SGRQ | INVOLVE B2334 | INHANCE B2335 | INLIGHT2 B2336 | INLIGHT1 B2346 | Total |
|----------|--------|---------------------------------------------|----------------|--------------|----------------|-----------------|-------|
| B1302    | To et al. | 150 μg: 104 | - | - | - | - | 104 |
|          |        | 300 μg: 106 | 365 | 350 | 302 | 189 | 945 |
|          |        | Placebo: 98 | 326 | 418 | 435 | 177 | 832 |
|          |        | Total: 300 | - | - | - | - | 300 |

Patients with cough

| Study ID | Author | Number of participants who completed the SGRQ | INVOLVE B2334 | INHANCE B2335 | INLIGHT2 B2336 | INLIGHT1 B2346 | Total |
|----------|--------|---------------------------------------------|----------------|--------------|----------------|-----------------|-------|
| B1302    | To et al. | 150 μg: 91 (87.5) | - | 325 (92.9) | - | - | 325 |
|          |        | 300 μg: 87 (82.1) | 332 (91.0) | 335 (92.8) | - | - | 335 |
|          |        | Placebo: 92 (93.9) | 292 (89.6) | 294 (70.3) | 246 (73.4) | 172 (97.2) | 172 |
|          |        | Total: 300 | - | - | - | - | 300 |

Patients with phlegm

| Study ID | Author | Number of participants who completed the SGRQ | INVOLVE B2334 | INHANCE B2335 | INLIGHT2 B2336 | INLIGHT1 B2346 | Total |
|----------|--------|---------------------------------------------|----------------|--------------|----------------|-----------------|-------|
| B1302    | To et al. | 150 μg: 88 (84.6) | - | 289 (82.6) | - | - | 289 |
|          |        | 300 μg: 95 (89.6) | 302 (82.7) | 297 (82.3) | - | - | 297 |
|          |        | Placebo: 89 (90.8) | 267 (81.9) | 267 (63.9) | 225 (67.2) | 155 (87.6) | 155 |
|          |        | Total: 300 | - | - | - | - | 300 |

Patients with dyspnea

| Study ID | Author | Number of participants who completed the SGRQ | INVOLVE B2334 | INHANCE B2335 | INLIGHT2 B2336 | INLIGHT1 B2346 | Total |
|----------|--------|---------------------------------------------|----------------|--------------|----------------|-----------------|-------|
| B1302    | To et al. | 150 μg: 89 (85.6) | - | 289 (82.6) | - | - | 289 |
|          |        | 300 μg: 83 (78.3) | 319 (87.4) | 297 (82.3) | - | - | 297 |
|          |        | Placebo: 85 (86.7) | 279 (85.6) | 267 (63.9) | 234 (69.9) | 167 (94.4) | 167 |
|          |        | Total: 300 | - | - | - | - | 300 |

Data are shown as the number (percent).
The effect of 150 μg indacaterol on cough

The effect of 300 μg indacaterol on cough

The effect of 150 μg indacaterol on phlegm

The effect of 300 μg indacaterol on phlegm

The effect of 150 μg indacaterol on dyspnea

The effect of 300 μg indacaterol on dyspnea

Fig. 1. The effect of 150 μg indacaterol on major respiratory symptoms; (A) effect on cough, (B) effect on phlegm, and (C) effect on dyspnea.

Fig. 2. The effect of 300 μg indacaterol on major respiratory symptoms; (A) effect on cough, (B) effect on phlegm, and (C) effect on dyspnea.

DISCUSSION

In our current review, we found that treatment with the new 24-hr, ultra-LABA indacaterol appears to have little effect on cough or phlegm in 3,325 patients with COPD. By contrast, the data show that indacaterol improved dyspnea compared with placebo. COPD is a heterogeneous disease and although chronic cough and sputum production are necessary components of the definition for COPD, changes in cough and phlegm symptoms themselves have not been well-studied. Quantifying the degree to which cough responds to treatment for COPD is diffi-
cult. Cough and phlegm in many COPD studies are just described as part of the total SGRQ score or the COPD assessment test (CAT); however, these tools are generally indicated for assessment of quality of life or health status rather than major symptoms in patients with mild to moderate lung function but with generally healthy status except cough or phlegm. Cough and phlegm does not stand out in these tools, which give a low weight to these two symptoms. Recently, newer instruments such as the exact questionnaires (19) were introduced. However, there is a lack of investigation of the effectiveness of these questionnaires.

A previous meta-analysis (11, 20) reported improvements in the symptom of breathlessness. They used a measurement involving a ratio of baseline dyspnea index (BDI)/transition dyspnea index (TDI) score. The BDI/TDI ratio considers three components—functional impairment, the magnitude of task, and the magnitude of effort—that provoke breathing difficulty. These measurements reflect the severity of patients’ feelings of dyspnea. Our results showing an improvement in the SGRQ symptom domain score of dyspnea coincide with this previous meta-analysis (11, 20). Likewise, the improvement in the SGRQ symptom domain score of cough or phlegm could be used for the evaluation of improvement in cough or phlegm symptoms. Several studies (21, 22) have reported that the symptom domain score in SGRQ could be represented and associated with cough or sputum; however, how much of an improvement of symptom score of the SGRQ would be required to achieve a minimal clinical threshold of importance was unclear. Although it may be arbitrary to define a change as an improvement when one or more symptom scores within the SGRQ decrease, we should be careful to make such an interpretation. In our current study, we sought to understand the potential effect of indacaterol on cough or sputum in addition to dyspnea. However, many clinical trials on COPD have not evaluated the effects of treatment on cough or sputum per se.

Based on our current findings, the ultra-LABA which is well-known to be one of best drugs for COPD treatment did not improve cough or phlegm symptoms in COPD patients. Previous studies (23, 24) have reported that beta2-agonists could improve the mucociliary function and decrease phlegm and cough symptoms. However, we did not find such an effect in our present investigation. Additionally, the effect of indacaterol on dyspnea did not show a dose-dependent correlation. Patients who were included in our current analysis had moderate to severe COPD and a mean FEV1 at approximately 50% of the normal value. The main symptoms might differ according to the FEV1 in COPD patients. Paradoxically, patients with mild to moderate COPD complain more about cough and phlegm impacts. We were not able to evaluate the effect of indacaterol on cough or sputum in a subgroup of patients with mild to moderate COPD, because we could not get access to the raw data. It is possible that our conclusions in relation to cough or phlegm may have been different if only patients with mild to moderate COPD had been evaluated. Further studies to evaluate subgroups of patients according to their lung function or other characteristics such as the frequency of exacerbation would likely be valuable.

There is a lack of COPD studies that have used cough or phlegm as outcomes per se. By contrast, the data show that indacaterol improved dyspnea compared with placebo. The effect of indacaterol on cough or phlegm has not typically been evaluated despite nearly all of the studies on indacaterol reporting a beneficial effect on dyspnea in COPD patients. We here investigated whether patients with COPD felt an improvement of symptoms such as cough, phlegm, and dyspnea after ultra LABA treatment compared to the placebo group. We conclude that compared to a placebo, a 12-week treatment of indacaterol, a long-acting beta-agonist, might not have a significant effect on cough or phlegm in stable COPD cases.

ACKNOWLEDGEMENTS

This investigator-initiated, post-hoc analysis was made possible because Novartis generously provided their data from five randomized controlled trials of indacaterol. Novartis played no role or influence of the implementation of this study except providing data. The authors thank Novartis for access to these findings.

DISCLOSURE

Oh YM has received honoraria/consulting fees for Dongwhapharm. Co., Ltd, MSD Korea, AstraZeneca Korea, GlaxoSmithKline Korea, Boehringer-Ingelheim Korea. For Novartis, Oh YM received honorarium that was not related to this study; he did not receive any honorarium or consulting fee in relation to this study. The other authors stated there was no conflict of interest to declare.

AUTHOR CONTRIBUTION

Study concept and design: Park J, Oh YM. Data acquisition and analysis: Park J, Lee JS. Data interpretation and analysis: Park J, Oh YM. Writing first draft: Park J. Critical revision: Oh YM, Rhee C. Approval of the final manuscript and submission: all authors.

ORCID

Jinkyeong Park  http://orcid.org/0000-0002-8833-9062
Chinkook Rhee  http://orcid.org/0000-0003-4533-7937
Yeon-Mok Oh  http://orcid.org/0000-0003-0116-4683
REFERENCES

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-8.
2. Lee JS, Rhee CK, Yoo KH, Lee JH, Yoon HI, Kim TH, Kim WI, Lee J, Lim SY, Park TS, et al. Three-month treatment and exacerbation in chronic obstructive pulmonary disease. J Korean Med Sci 2015; 30: 54-9.
3. Figarska SM, Boezen HM, Vonk JM. Dyspnea severity, changes in dyspnea status and mortality in the general population: the Vlagtwedde/Vlaardingen study. Eur J Epidemiol 2012; 27: 867-76.
4. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-40.
5. Müllerová H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One 2014; 9: e85540.
6. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J 2002; 20: 799-805.
7. Calverley PM. Cough in chronic obstructive pulmonary disease: is it important and what are the effects of treatment? Cough 2013; 9: 17.
8. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carré P, Perez T, Roche N. Initiatives Bronchopneumopathie Chronique Obstructive Scientific Committee. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975-82.
9. Beeth KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients. COPD. COPD 2011; 8: 340-5.
10. Watz H, Krippner F, Kirsten A, Magnussen H, Vogelmeier C. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease—a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med 2014; 14: 158.
11. Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med 2013; 13: 26.
12. To Y, Kinoshita M, Lee SH, Hang LW, Ichinose M, Fukuchi Y, Kitawaki T, Okino N, Prasad N, Lawrence D, et al. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population. Respir Med 2012; 106: 1715-21.
13. Dahl R, Chung KF, Buli R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, et al.; INVOLVE (Indacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473-9.
14. Donohue JF, Fogarty C, Lütvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, et al.; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155-62.
15. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37: 273-9.
16. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B; INLIGHT-1 study group. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10: 11.
17. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28: 105-14.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
19. Leidy NK, Murray LT. Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD 2013; 10: 393-8.
20. Chung VC, Ma PH, Hui DS, Tam WW, Tang JL. Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One 2013; 8: e70784.
21. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-7.
22. Chang JA, Curtis JR, Patrick DL, Baghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999; 116: 1175-82.
23. Devalia JL, Sapsford RJ, Rusznak C, Toumbis MJ, Davies RJ. The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro. Pulm Pharmacol 1992; 5: 257-63.
24. Devalia JL, Sapsford RJ, Rusznak C, Toumbis MJ, Davies RJ. The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro. Pulm Pharmacol 1992; 5: 257-63.